Galectin Therapeutics Reports 2025 Financial Results and Provides Key Business Update

Summary

• Meaningful progress in belapectin clinical program for MASH cirrhosis and portal hypertension.
• Strengthened financial position with \$10 million additional credit line, extending cash runway through April 2027.
• NAVIGATE trial data continues to support belapectin’s potential as first-in-class therapy for MASH cirrhosis—no approved competitors currently exist.
• New Board appointment: Dr. Henry Brem, renowned neurosurgeon-scientist, to support clinical development.
• Multiple upcoming presentations at the EASL Congress, reflecting continued scientific community interest.
• Significant reductions in research & development expenses after NAVIGATE trial completion; net loss narrowed, but company remains unprofitable.

Business and Clinical Program Highlights

Galectin Therapeutics (NASDAQ: GALT) announced its full-year 2025 financial results and provided a comprehensive business update, marking a significant year for its flagship belapectin program targeting MASH (Metabolic dysfunction-Associated Steatohepatitis) cirrhosis with portal hypertension. CEO Joel Lewis emphasized that the company is at a key inflection point, having made substantial headway in data analysis and regulatory engagement.

Belapectin – A Potential Breakthrough for MASH Cirrhosis

• The NAVIGATE Phase 2b/3 trial (NCT04365868) is a global, randomized, double-blind, placebo-controlled study evaluating belapectin (2 mg/kg or 4 mg/kg IV every two weeks for 18 months) in preventing esophageal varices in patients with MASH cirrhosis.
• Key Efficacy Results:
  • In the intent-to-treat population (n=355), belapectin 2 mg/kg reduced varices incidence by 43.2% vs. placebo, though the composite endpoint did not reach statistical significance.
  • In the per-protocol population (n=287), belapectin 2 mg/kg reduced varices incidence by 49.3% vs. placebo (nominal p = 0.04).
  • In U.S. per-protocol patients (n=186), belapectin 2 mg/kg reduced the incidence by a remarkable 68.1% vs. placebo (p = 0.02).
• Safety Profile: Comparable rates of treatment-emergent adverse events, serious adverse events, and discontinuations across all treatment groups. No drug-related serious adverse events were reported.
• Biomarker and Mechanistic Insights:
  • Consistent effects across non-invasive markers of fibrosis and disease progression (e.g., FibroScan® liver stiffness, ELF score, PRO-C3).
  • Additional mechanistic analyses (YKL-40, PRO-C4) support belapectin’s biological activity in reducing inflammation and fibrogenesis.
  • Analyses using Baveno VII criteria suggested improvements in portal hypertension risk category and reduced hepatic decompensation risk vs. placebo.
• Scientific Engagement: Key findings discussed at a March 2026 virtual KOL event with top hepatology experts. Multiple NAVIGATE abstracts (including an oral presentation) have been accepted for the prestigious EASL 2026 Congress, underscoring the strong scientific interest in the program.
• Regulatory Outlook: Company expects to meet with the FDA in Q2 2026 to discuss the next steps for advancing belapectin.

Financial Update

• Cash Position: \$17.7 million in cash and equivalents as of December 31, 2025, with an additional \$10 million credit line secured from Chairman Dick Uihlein—sufficient runway for planned operations and R&D through April 2027.
• R&D Expenses: \$14.3 million in 2025 (down from \$36.6 million in 2024), reflecting completion of major clinical trial activities.
• G&A Expenses: \$5.8 million in 2025 (vs \$5.9 million in 2024), essentially flat year-over-year.
• Net Loss: \$31.0 million for 2025 (or \$0.48 per share), a notable improvement from \$47.2 million (\$0.76 per share) in 2024, driven primarily by lower R&D outlays.
• Stockholders’ Equity: Remains negative at \$(127.9) million at year-end 2025, reflecting continued operating losses and accumulated deficit.

Corporate Developments

• Board Strengthening: Appointment of Dr. Henry Brem, a distinguished neurosurgeon-scientist, to the Board. His expertise in translational medicine and clinical development is expected to support the next phase of belapectin’s progress.
• Pipeline Beyond Liver Disease: Additional programs in combination immunotherapy for advanced cancers are being considered, but progress will depend on securing suitable partnership(s).

Potential Share Price Catalysts & Risks

• Pivotal Clinical Data: The NAVIGATE trial’s positive biomarker and clinical data in MASH cirrhosis, especially in the U.S. subgroup, highlight belapectin’s potential as a first-in-class therapy—an area with no approved competitors. This could be highly price-sensitive if the FDA provides a favorable regulatory path.
• Regulatory Milestones: The upcoming FDA meeting in Q2 2026 and new data presentations at EASL may significantly impact sentiment and valuation, depending on regulatory feedback and broader scientific acceptance.
• Financial Stability: The extended cash runway reduces near-term dilution risk, but the company remains loss-making with negative equity, and long-term funding needs persist.
• Risks: As always, there is risk that further analysis of NAVIGATE data, regulatory reviews, or subsequent trials may not confirm efficacy or safety, or that the company may not secure necessary partnerships or financing for future development.

Conclusion

Galectin Therapeutics has advanced its lead asset, belapectin, with encouraging results in a large, global Phase 2b/3 trial for MASH cirrhosis with portal hypertension. The data, particularly in U.S. patients, show substantial risk reduction for varices—a key complication in cirrhosis. With an extended cash runway, new Board expertise, and multiple high-profile scientific presentations upcoming, the company is well-positioned for critical regulatory discussions in 2026. However, investors should remain mindful of ongoing losses, negative equity, and the uncertainties inherent in late-stage biotech development.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation. Forward-looking statements are subject to risks and uncertainties. Investors should review the company’s filings with the SEC and consult a qualified financial advisor before making investment decisions.

View GALECTIN THERAPEUTICS INC Historical chart here